NAHPC CEO: Souped-Up Value Assessment Entity A Much-Needed Rx Pricing Reform

The establishment of government-endorsed value assessment entities to ferret out the fairest value of prescription drugs when they enter market would provide employers and health care purchasers a different way of determining where to place new treatments in their formularies without having to engage with the current rebate model that comes with perverse incentives for pharmacy benefit managers and insurers to favor preferential placement for the most expensive drugs, Shawn Gremminger, president and CEO of the National Alliance of Healthcare Purchaser Coalitions (NAHCP), recently told Inside Health Policy.